Moshe Ornstein
Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Moshe Ornstein

Oncology
Cleveland Clinic
Cleveland Clinic Main Campus
10201 Carnegie Avenue, 
Cleveland, OH 
On Staff At
Offers Telehealth
20 Years of Experience

Distinguished in WT1-Related Wilms Tumor Syndromes
Cleveland Clinic
Cleveland Clinic Main Campus
10201 Carnegie Avenue, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Moshe Ornstein is an Oncologist in Cleveland, Ohio. Dr. Ornstein has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Gamma Knife Radiosurgery.

His clinical research consists of co-authoring 80 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Touro College, 2005
Residency
Cleveland Clinic
Specialties
Oncology
Licenses
Internal Medicine in OH
Board Certifications
American Board Of Internal Medicine, 2017
Fellowships
Cleveland Clinic
Hospital Affiliations
Cleveland Clinic Avon Hospital
Cleveland Clinic
Mercy Medical Center
Medina Hospital
Hillcrest Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106
Call: 866-223-8100

Additional Areas of Focus

Dr. Ornstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
Enrollment Status: Terminated
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Avelumab
Study Phase: Phase 2
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
The Association Between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men With Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy After Treatment With Apalutamide and Leuprolide
The Association Between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men With Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy After Treatment With Apalutamide and Leuprolide
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug, Procedure
Study Phase: Phase 2
View 5 Less Clinical Trials

80 Total Publications

From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma.
From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma.
Journal: JCO oncology practice
Published: April 09, 2025
View All 80 Publications
Similar Doctors
Timothy Gilligan
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Timothy Gilligan
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Timothy Gilligan
Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.4 miles away)
866-223-8100
Experience:
39+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Gilligan is an Oncologist in Cleveland, Ohio. Dr. Gilligan has been practicing medicine for over 39 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Testicular Cancer, Urothelial Cancer, Nephrectomy, and Gamma Knife Radiosurgery.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ryan Berglund
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ryan Berglund
Oncology

Hillcrest Medical Building Atrium

6770 Mayfield Road, 
Mayfield Hts, OH 
 (9.8 miles away)
440-312-4500
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ryan Berglund is an Oncologist in Mayfield Hts, Ohio. Dr. Berglund has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Bladder Cancer, Urothelial Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Nima Almassi
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nima Almassi
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nima Almassi
Oncology

Cleveland Clinic Main Campus

2050 East 96th Street, 
Cleveland, OH 
 (1.0 miles away)
216-444-5600
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nima Almassi is an Oncologist in Cleveland, Ohio. Dr. Almassi has been practicing medicine for over 19 years and is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ornstein's expertise for a condition
ConditionClose
  • Elite
  • Renal Cell Carcinoma (RCC)
    Dr. Ornstein is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Ornstein is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Bladder Cancer
    Dr. Ornstein is
    Distinguished
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Ornstein is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Ornstein is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Prostate Cancer
    Dr. Ornstein is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Familial Wilms Tumor 2
    Dr. Ornstein is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
View All 10 Distinguished Conditions
  • Advanced
  • Astrocytoma
    Dr. Ornstein is
    Advanced
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Ornstein is
    Advanced
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Choriocarcinoma
    Dr. Ornstein is
    Advanced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Ornstein is
    Advanced
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Ependymoma
    Dr. Ornstein is
    Advanced
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Glioblastoma
    Dr. Ornstein is
    Advanced
    . Learn about Glioblastoma.
    See more Glioblastoma experts
View All 17 Advanced Conditions
  • Experienced
  • Acute Myeloid Leukemia (AML)
    Dr. Ornstein is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adrenal Cancer
    Dr. Ornstein is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Ornstein is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • Agranulocytosis
    Dr. Ornstein is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Ornstein is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Alveolar Soft Part Sarcoma
    Dr. Ornstein is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
View All 76 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved